Navigation Links
Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results

LEXINGTON, Mass., Feb. 4 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) (the "Company") today announced its consolidated results of operations for the first quarter of fiscal 2009, ended December 31, 2008.

The Company reported revenues of $26.4 million and a consolidated net loss of $7.6 million or $0.10 per share for the quarter ended December 31, 2008. This compares to revenues of $16.4 million and a consolidated net loss of $14.7 million or $0.19 per share for the quarter ended December 31, 2007.

At December 31, 2008, the Company had consolidated cash and cash equivalents totaling approximately $125.6 million.

Financial Results

Total consolidated revenues for the quarter ended December 31, 2008 were $26.4 million, an increase of 61% from the $16.4 million reported for the quarter ended December 31, 2007. The primary components of revenue for the quarter ended December 31, 2008 were $13.0 million from the recognition of revenue associated with the SANCTURA(R) brand, $6.8 million from sales of VANTAS(R), and $5.9 million from sales of SUPPRELIN(R) LA.

Cost of product revenue for the quarter ended December 31, 2008 was $6.5 million, an increase of 12% from the $5.9 million reported for the quarter ended December 31, 2007. Cost of product revenue in the current quarter relates primarily to costs associated with the SANCTURA brand, including royalties on sales of SANCTURA and SANCTURA XR(TM) that are reimbursed by Allergan, and costs associated with VANTAS and SUPPRELIN LA.

Research and development expenses for the quarter ended December 31, 2008 were $5.2 million, a decrease of 19% from the $6.4 million reported for the quarter ended December 31, 2007. Marketing, general and administrative expenses for the quarter ended December 31, 2008 were $15.9 million, a decrease of 10% from the $17.8 million reported for the quarter ended December 31, 2007.

Interest expense of $6.3 million for the quarter ended December 31, 2008 related to the Company's Convertible Notes and Non-recourse Notes.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA XR(TM) and SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(TM) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, octreotide for acromegaly, and pagoclone for stuttering.


SANCTURA(R) and SANCTURA XR(TM) belong to a class of anticholinergic compounds known as muscarinic receptor antagonists. These compounds relax detrusor smooth muscle tissue found in the bladder, thus decreasing bladder contractions. Overactive or unstable detrusor muscle function is believed to be the cause of overactive bladder.

SANCTURA and SANCTURA XR possess a quaternary ammonium structure that may be instrumental in the low incidence of CNS side-effects. At therapeutic concentrations in vitro, SANCTURA does not interact with drugs metabolized by the Cytochrome P-450 system, a metabolic pathway commonly associated with drug-drug interactions, and the majority of the absorbed dose is excreted largely unchanged into the urine.

Patients who have urinary retention, gastric retention, uncontrolled narrow-angle glaucoma or hypersensitivity to SANCTURA should not use SANCTURA.


VANTAS(R) is a soft and flexible 12-month hydrogel implant that provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer. VANTAS is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any components in VANTAS.


SUPPRELIN(R) LA is a subcutaneous implant indicated for the treatment of central precocious puberty (CPP), the premature onset of puberty in children. It utilizes the hydron implant technology and is specifically designed to provide a continuous release over 12 months of the gonadotropin releasing hormone (GnRH) agonist, histrelin. SUPPRELIN LA is contraindicated in patients with hypersensitivity to GnRH or GnRH analogs.


DELATESTRYL(R) is an injectable testosterone preparation for the treatment of male hypogonadism. DELATESTRYL is contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate.

Merger Agreement with Endo Pharmaceuticals

On January 5, 2009, the Company entered into a definitive merger agreement with Endo Pharmaceuticals Holdings Inc. ("Endo"), a Delaware corporation, pursuant to which BTB Purchaser Inc. ("Purchaser"), a Delaware corporation and a direct wholly-owned subsidiary of Endo, has agreed to purchase all of the issued and outstanding shares of common stock, par value $0.001 per share, of the Company at a purchase price of $4.50 per share in cash (less any required withholding taxes and without interest), plus contractual rights to receive up to an additional $3.00 per share in contingent cash consideration payments (less any required withholding taxes) payable by Endo in the future upon achievement of certain milestones related to NEBIDO(R) (in development for hypogonadism) and octreotide (in development for acromegaly and carcinoid syndrome), two of the Company's primary product candidates. The acquisition will be effected by means of a tender offer for all the outstanding shares of the Company's common stock, followed by a merger in which the holders of any remaining outstanding shares of the Company's common stock will receive the same consideration as the consideration paid to tendering holders of the Company's common stock in the tender offer. The tender offer commenced on January 7, 2009 and is expected to close before the end of the Company's second fiscal quarter of 2009. The tender offer is conditioned upon the tender of a majority of the outstanding shares of the Company's common stock and is also subject to other customary closing conditions. Due to the potential acquisition by Endo, the Company will not be providing 2009 financial guidance. For more detail regarding the tender offer, see "Additional Important Information" set forth below.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA, SANCTURA XR, NEBIDO, VANTAS and SUPPRELIN LA; effectiveness of our sales force; competition and its effect on pricing, spending, third-party relationships and revenues; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; risks associated with being a manufacturer of some of our products; risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; reliance on intellectual property and having limited patents and proprietary rights; dependence on market exclusivity, changes in reimbursement policies and/or rates for SANCTURA, SANCTURA XR, VANTAS, SUPPRELIN LA, DELATESTRYL and any future products; acceptance by the healthcare community of our approved products and product candidates; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR; product liability and insurance uncertainties; risks relating to the Redux-related litigation; need for additional funds and corporate partners, including for the development of our products; history of operating losses and expectation of future losses; uncertainties relating to controls over financial reporting; difficulties in managing our growth; valuation of our Common Stock; risks related to repayment of debts; risks related to increased leverage; general worldwide economic conditions and related uncertainties; and other risks. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Additional Important Information

This press release is for informational purposes only and does not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell securities of the Company. The tender offer is being made pursuant to a tender offer statement on Schedule TO (including the offer to purchase, letter of transmittal and other related tender offer materials, which were mailed to the Company's shareholders) filed by Endo and Purchaser with the SEC on January 7, 2009. In addition, on January 7, 2009, the Company filed with the SEC a solicitation/recommendation statement on Schedule 14D-9 with respect to the tender offer, which was mailed to the Company's shareholders. Investors and the Company's shareholders are urged to read both the tender offer statement (and related materials), as it may be amended from time to time, and the solicitation/recommendation statement, as it may be amended from time to time, because they contain important information, including the various terms of, and conditions to, the tender offer, that should be read carefully before any decision is made with respect to the tender offer. Investors and the Company's shareholders may obtain a free copy of these statements and other documents filed by Endo, Purchaser, the Company and their affiliates with the SEC at the website maintained by the SEC at In addition, the tender offer statement and related materials may be obtained for free at Endo's website at or by directing such requests to Endo (Investor Relations) at (610) 459-7158,, or by calling MacKenzie Partners, the information agent for the offer toll-free at (800) 322-2885. The solicitation/recommendation statement and such other documents may be obtained by directing such requests to the Company (Investor Relations) at (781) 402-3405 or

                            INDEVUS PHARMACEUTICALS, INC.
                For the three months ended December 31, 2008 and 2007
                    (Amounts in thousands except per share data)

                                           For the three months ended
                                                   December 31,
                                               2008           2007

     Total revenues                          $26,397        $16,398

     Costs and expenses:
     Cost of revenues                          6,534          5,855
      Research and development                 5,188          6,391
      Marketing, general and administrative   15,948         17,766
      Amortization of intangibles                637            497

           Total costs and expenses           28,307         30,509
     Loss from operations                     (1,910)       (14,111)

     Investment income                           596          1,120
     Interest expense                         (6,272)        (1,712)
     Net loss                                $(7,586)      $(14,703)

      Net loss per common share:
             Basic and diluted                $(0.10)        $(0.19)
      Weighted average common shares:
             Basic and diluted                77,616         76,307

                            INDEVUS PHARMACEUTICALS, INC.
                               (Amounts in thousands)

                                           December 31,   September 30,
                                               2008           2008

     Cash and cash equivalents              $125,555       $131,306
     Restricted cash                           8,545         10,000
     Goodwill                                 48,244         48,244
     Intangible assets, net                   30,218         30,855
     Other assets                             43,734         42,597
             Total assets                   $256,296       $263,002

     Convertible notes                       $70,736        $70,187
     Non-recourse notes                      105,000        105,000
     Deferred revenue                        184,312        189,015
     Other liabilities                        32,144         28,986

     Capital                                 513,742        511,866
     Accumulated deficit                    (649,638)      (642,052)
       Total stockholders' deficit          (135,896)      (130,186)
         Total liabilities and
          stockholders' deficit             $256,296       $263,002


    Michael W. Rogers                  Robin L. DeCarlo
    EVP and Chief Financial Officer    Sr. Director, Corporate Communications
    (781) 861-8444                     (781) 402-3405

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
2. Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
3. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
4. Indevus Pharmaceuticals Provides Update on NEBIDO(R) NDA Status
5. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
6. Indevus Pharmaceuticals Announces Retirement Plans For Its CEO and Chairman
7. Indevus To Announce First Quarter Fiscal 2008 Financial Results On Thursday, February 7, 2008
8. Indevus Pharmaceuticals To Present at RBC Capital Markets Conference
9. FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
10. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
11. Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals
Post Your Comments:
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology: